Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2246285 | 0.88 | KEAP1 (0.45) | GNAI3GNAO1GNAI1CHRM3SMN1; SMN2 | |
| SCHEMBL25363068 | 0.88 | ALOX15 (0.41) | ALOX15CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6827945 | 0.88 | ALOX15 (0.41) | ALOX15CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25365601 | 0.88 | ALOX15 (0.41) | ALOX15CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1463883 | 0.86 | GNAI3 (0.42) | GNAI3GNAO1GNAI1CHRM3SMN1; SMN2 | |
| SCHEMBL16065870 | 0.83 | LMNA (0.35) | CARM1PRMT6PRMT1PRMT8SMN1; SMN2 | |
| SCHEMBL19014577 | 0.82 | DPP4 (0.34) | SMN1; SMN2LMNADPP4 | |
| SCHEMBL8860965 | 0.80 | ALOX15 (0.43) | ALOX15CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12714801 | 0.80 | DRD2 (0.47) | GNAI3GNAO1GNAI1 | |
| SCHEMBL15806911 | 0.79 | SIGMAR1 (0.41) | GNAI3GNAO1GNAI1CHRM3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-02-20 | — | — | US | disclosed |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-12-26 | — | — | US | disclosed |
| CN-118414171-A | Oligosaccharide complexes and uses | 生物技术公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118401538-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4401838-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401789-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| CN-118369122-A | Oligosaccharide complex and use thereof | 生物技术公司 | 2024-07-19 | — | — | CN | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0669830-A4 | SUBSTITUTED DIPEPTIDE ANALOGS PROMOTE RELEASE OF GROWTH HORMONE. | MERCK & CO INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0682654-A4 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE. | MERCK & CO INC (US) | 1996-01-17 | — | — | EP | disclosed |
| EP-0682654-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669830-A1 | SUBSTITUTED DIPEPTIDE ANALOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO. INC. (US) | 1995-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057944-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | FUT6, NSUN3, OSTC | ALOX15 4137/4885CARM1 3621/4885PRMT6 2420/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | ALOX15 1466/4885CARM1 4524/4885PRMT6 3751/4885 |
| US-20240425541-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, SNRPA, RNASE1 | ALOX15 2873/4885CARM1 2906/4885PRMT6 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.